Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05484349 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT05484349 · ClinicalTrials.gov record · last posted 2024-08-01

TIzanidine for the Preventive Treatment of Episodic MigrainE （TIME）

StatusUnknown
PhasePhase 3
Started2023-06-01
View on ClinicalTrials.gov ↗
Record status
This record was last updated August 1, 2024 (before its estimated December 25, 2025 completion). Its status may not reflect the trial's current state.
from the ClinicalTrials.gov record
In this study,189 adult migraine patients aged 18-65 years (diagnosed with migraine without aura and/or migraine with aura, with at least a 1-year history)will be collected to evaluate the efficacy, safety and tolerability of Tizanidine Hydrochloride in preventing migraine attacks in episodic migraine in adults.

Protocol amendment history 2 changes detected by DataLookout

2026-08-09
Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University → Second Affiliated Hospital, Zhejiang University, School of Medicine
WasSecond Affiliated Hospital, School of Medicine, Zhejiang University
NowSecond Affiliated Hospital, Zhejiang University, School of Medicine
2026-08-02
Trial status changed: Recruiting → Unknown
Trial Details
NCT Number NCT05484349
Lead Sponsor Second Affiliated Hospital, School of Medicine, Zhejiang University
Collaborators: Sichuan Credit Pharmaceutical Co., Ltd.
Conditions Migraine Without Aura, Migraine With Aura
Enrollment 189 participants
Start Date 2023-06-01
Primary Completion 2025-12-25 (estimated)
Study Completion 2025-12-25 (estimated)
Updated on ClinicalTrials.gov 2024-08-01